Clinical Trials · NCT02668172

Pasireotide LAR and Pegvisomant Study in Acromegaly

Name: Pasireotide LAR and Pegvisomant Study in Acromegaly
Creator: Peptide Science Daily
License: https://clinicaltrials.gov/about-site/terms-conditions

UnknownPhase 4Octreotide Lanreotide

Phase: Phase 4
Recruitment status: Unknown
Sponsor: Erasmus Medical Center
Enrollment: 60
Start date: Aug 2015
Locations: 1 site, Netherlands
Primary endpoint: The proportion of patients with normalized IGF1 levels at 24 weeks in the pasireotide LAR monotherapy group and in the pasireotide LAR combined with pegvisomant group

View Octreotide compound reference